United States: Draft Guidance Outlines Recommendations For Formal Meetings Between FDA And Biosimilar Sponsors And Applicants

The U.S. Food and Drug Administration (FDA) recently released the fourth in a series of draft guidance documents on the approval pathway for biologicals that are biosimilar to or interchangeable with a reference biological product. This latest guidance focuses on the mechanics of requesting, preparing for, scheduling, conducting and documenting a formal meeting with the FDA in connection with a sponsor's biosimilar development program. Because of the importance of obtaining application-related guidance from the FDA in this new program, and in the absence of regulations, companies involved in the development of biosimilars should take note of the conditions and process set forth by the FDA for these meetings.


The U.S. Food and Drug Administration (FDA) recently released draft guidance entitled "Formal Meetings Between the FDA and Biosimilar Biological Product Sponsors or Applicants." The draft guidance is the latest in a series of draft guidance documents in which the agency describes how it intends to implement the biosimilar approval pathway created by the Biologics Price Competition and Innovation Act of 2009 (BPCI Act). A biological product is "biosimilar" to an FDA-licensed biological (i.e., the reference product) if it is highly similar to the reference product notwithstanding minor differences in clinically inactive components, and there are no clinically meaningful differences between the products in terms of safety, purity and potency. See BPCI Act § 7002(b)(3). This particular document, issued in connection with the Biosimilar User Fee Act of 2012 (enacted as part of the Food and Drug Administration Safety and Innovation Act (FDASIA), Pub. L. No. 112-144, § 401 et seq.), focuses on the procedural requirements for formal meetings with the FDA regarding the development of biosimilars. Because of the importance of obtaining application-related guidance from the FDA in this new program, and in the absence of regulations, companies involved in the development of biosimilars should take note of the conditions and process set forth by the FDA for these meetings.

Highlights of the draft guidance include the following:

  • The agency will participate in five types of formal meetings with biosimilar sponsors and applicants. The main characteristics of each type of meeting are summarized in the following table.

Type of Meeting

Purpose of Meeting

Type of Data Reviewed

Meeting Target Date

Agency Response Time to Meeting Request

Biosimilar Initial Advisory meeting

  • Initial assessment
  • Limited to a general discussion regarding feasibility of the biosimilar pathway for a particular product
  • If the development of a biosimilar is feasible, FDA offers general advice as to the expected content of the development program
  • Applicants expected to provide "preliminary comparative analytical similarity data"
  • Agency will not engage in the substantive review of summary data or full study reports
  • Within 90 calendar days of FDA receipt of written meeting request and meeting package
  • Within 21 calendar days of receipt of the request and meeting package

Biological Product Development (BDP) Type 1 meeting

  • Meeting necessary for an otherwise stalled BPD program to proceed

N/A

  • Within 30 calendar days of FDA receipt of a written meeting request and meeting package
  • Within 14 calendar days of receipt of the request and meeting package

BPD Type 2 meeting

  • Discuss a specific issue (e.g., proposed study design, endpoints) or questions where the FDA will provide targeted advice
  • Agency will engage in the substantive review of summary data
  • Agency will not review full study reports
  • Within 75 calendar days of FDA receipt of a written meeting request and meeting package
  • Within 21 calendar days of receipt of the request and meeting package

BPD Type 3 meeting

  • In-depth review of data and the provision of advice regarding an ongoing program (including need for additional studies)
  • Meeting includes substantive review of full study report(s)
  • Within 120 calendar days of FDA receipt of a written meeting request and meeting package
  • Within 21 calendar days of receipt of the request and meeting package

BPD Type 4 meeting

  • Discuss the format and content of a biosimilar application (or supplement)

N/A

  • Within 60 calendar days of FDA receipt of a written meeting request and meeting package
  • Within 21 calendar days of receipt of the request and meeting package
  • Sponsors and applicants must pay an annual, per-product fee to participate in the BPD meeting program (at least insofar as they would like to participate in a meeting other than an Initial Advisory meeting). Sponsors and applicants must pay an annual per-product fee to participate in a Type 1, 2, 3 or 4 meeting. There are three types of fees:
    • Initial fee—The initial fee is due on the date that a sponsor or applicant submits an investigational new drug application (IND) for an investigation that the FDA determines is intended to support an application for a biosimilar, or within five calendar days of the agency's decision to grant a Type 1–4 meeting, whichever occurs first. The amount of the initial fee is 10 percent of the fee rate established under the Prescription Drug User Fee Act (PDUFA) for a human drug application requiring clinical data ($195,880 in FY 2013).
    • Annual fee—Beginning in the fiscal year after which the sponsor or applicant pays the initial fee, an annual fee will be assessed until the sponsor or applicant submits a marketing application that is accepted for filing or discontinues participation in the BPD program. The amount of the annual fee is 10 percent of the fee rate established under PDUFA for a human drug application requiring clinical data ($195,880 in FY 2013).
    • Reactivation fee—If the sponsor or applicant discontinues participation in the program but later wishes to re-engage the agency on the development of the product, the reactivation fee is due on the date that the sponsor or applicant submits an IND for an investigation that the FDA determines is intended to support an application for a biosimilar, or within five calendar days after the FDA grants the sponsor's request for a Type 1–4 meeting, whichever occurs first. The amount of the reactivation fee is 20 percent of the fee rate established under PDUFA for a human drug application requiring clinical data ($391,760 in FY 2013).

      Failure to pay the initial or reactivation fee within five calendar days after a meeting request is officially granted will result in cancellation of the meeting. Similarly, if a sponsor is in arrears with regard to payment of the annual fee, the FDA will deny the sponsor's request for a meeting and/or cancel any scheduled meetings for that product.
  • Sponsors and applicants that wish to meet with the FDA should submit a meeting request and a meeting package. The meeting request should include adequate information for the FDA to assess the potential utility of the meeting and to identify FDA staff necessary to discuss proposed agenda items, while the meeting package should provide information relevant to the discussion topics and enable the agency to prepare adequately for the meeting. As illustrated in the following table, the requirements for these documents are very similar.

Meeting Request

Meeting Package

  • Product name
  • Application number (if applicable)
  • Proposed non-proprietary name (or non-proprietary name if post-licensure)
  • Structure (if applicable)
  • Reference product name
  • Proposed indication(s) or context of product development
  • Meeting type requested (with rationale)
  • Brief statement of purpose of the meeting (including a brief background of the issues underlying the agenda, which provides enough information to facilitate understanding of the issues)
  • List of specific objectives/outcomes expected from meeting
  • Proposed agenda (with estimated times needed for each item)
  • List of precise questions, grouped by discipline (with brief explanation of context and purpose of each question)
  • List of all individuals (with titles and affiliations) who will attend the requested meeting from the sponsor's or applicant's organization and consultants (an updated list of attendees should be provided to the agency at least one week before the meeting)
  • List of FDA staff (if known) asked to participate in the meeting
  • Suggested dates and times (within or beyond the appropriate timeframe for the meeting being requested)
  • Proposed format of the meeting (i.e., face-to-face meeting, teleconference, video conference, etc.)
  • Product name
  • Application number (if applicable)
  • Proposed non-proprietary name (or non-proprietary name if post-licensure)
  • Structure (if applicable)
  • Reference product name
  • Proposed indication(s) or context of product development
  • Dosage form
  • Route of administration
  • Dosing regimen (frequency and duration)
  • Presentation(s)
  • List of sponsor or applicant attendees, affiliations and titles
  • Background section that provides a brief history of the development program and the status of product development (e.g., chemistry, manufacturing and controls, nonclinical and clinical (including any development outside the United States, if applicable))
  • Brief statement summarizing the purpose of the meeting
  • Proposed agenda
  • List of questions for discussion (grouped by discipline, with a brief summary of each question to explain the need for context for the question)
  • Data to support discussion organized by discipline and question

If a meeting package is not submitted with the meeting request, the meeting request will be considered incomplete and the FDA will generally deny the meeting request.

If a meeting request is granted, the agency will notify the sponsor or applicant in writing of the decision and schedule the meeting by determining the meeting type, date, length, time, place and format (e.g., face-to-face, teleconference). Note: The agency may determine that a different meeting type is more appropriate than the type requested and grant a meeting of a different type. If a meeting request is denied, the sponsor or applicant will be notified and the notification will include an explanation as to the reason for the denial.

In addition to the items described above, the draft guidance addresses issues related to rescheduling meetings, cancelling meetings, pre-meeting communications between the sponsor or applicant and the agency, procedures for the conduct of meetings, documentation of meetings (i.e., minutes) and resolution of disputes regarding minutes.

Interested parties should submit comments on the draft guidance by May 31, 2013.

Implications

In releasing this draft guidance, the FDA has taken another step toward providing sponsors and applicants with a comprehensive overview of its vision for the implementation of the biosimilar approval pathway. It is apparent from earlier guidance issued by the agency that these meetings will be critical to the review and approval process for biosimilars—more so than is typical in the review process for small molecule drugs. As such, potential sponsors and applicants should participate in these meetings in a stepwise manner, and should use such meetings as avenues for substantive discussions and to define the pathway to securing approval. Potential sponsors and applicants now have written guidance regarding the information the agency indicates it needs to provide meaningful feedback on a biosimilar development program.

However, it remains clear that the agency continues to have serious concerns about the viability of the biosimilar pathway. Consistent with its position in last year's draft guidance, the agency suggests in this latest guidance that, for at least some reference biologicals, it may not be possible for an applicant to establish biosimilarity or interchangeability.

Finally, although this is the fourth draft guidance that the agency has released with respect to the biosimilar approval pathway, a number of important issues remain unaddressed, including whether biosimilar products will have the same non-proprietary name as reference biologics. Meetings between the agency and applicants will form an essential part of an iterative process which will help define the pathway. Reference manufacturers and biosimilar sponsors and applicants alike should also continue to monitor communications from the FDA for further guidance on this and other issues.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Emails

From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.